Your browser doesn't support javascript.
loading
Larynx proteomics after jellyfish collagen IL: Increased ECM/collagen and suppressed inflammation.
Bowen, Andrew J; Ekbom, Dale C; Hunter, Danielle; Voss, Stephen; Bartemes, Kathleen; Mearns-Spragg, Andrew; Oldenburg, Michael S; San-Marina, Serban.
Afiliação
  • Bowen AJ; Mayo Clinic ENT Rochester Minnesota USA.
  • Ekbom DC; Mayo Clinic ENT Rochester Minnesota USA.
  • Hunter D; Mayo Clinic ENT Rochester Minnesota USA.
  • Voss S; Mayo Clinic ENT Rochester Minnesota USA.
  • Bartemes K; Mayo Clinic ENT Rochester Minnesota USA.
  • Mearns-Spragg A; Jellagen Ltd. Wentloog Industrial Estate Cardiff UK.
  • Oldenburg MS; Prevea Health Services Green Bay Wisconsin USA.
  • San-Marina S; Mayo Clinic ENT Rochester Minnesota USA.
Laryngoscope Investig Otolaryngol ; 7(5): 1513-1520, 2022 Oct.
Article em En | MEDLINE | ID: mdl-36258863
ABSTRACT
Objectives/

Hypothesis:

Compare proteomic profiles of rabbit vocal folds (VFs) injected with micronized cross-linked jellyfish collagen "collagen Type 0" (MX-JC) against two clinical products for injection medialization laryngoplasty (IL). Study

Design:

Animal model.

Methods:

Left recurrent laryngeal nerve sectioning and IL were performed in New Zealand White rabbits (N = 6/group). Group 1 received (MX-JC) and adipose-derived stem cells (ADSCs), Group 2, MX-JC alone; Group 3, cross-linked hyaluronic acid; and Group 4, micronized acellular dermis. Animals were sacrificed at 4 and 12 weeks. Proteomic profiling of injected versus noninjected VFs by nano-liquid chromatography, tandem mass spectrometry, and reactome gene ontology analysis was performed.

Results:

Overall, 37-61 proteins were found to be upregulated and 60-284 downregulated in injected versus non-injected VFs (>1.5 fold, false discovery rate-adjusted p < .05). Over-representation analysis (% of total) revealed top up-regulated pathways at 4 and 12 weeks, respectively Group 1, keratan sulfate metabolism (46%) and cellular processes (29%); Group 2, extracellular matrix (ECM)/collagen processes (33%) and beta oxidation (39%); Group 3, cellular processes (50%) and energy metabolism (100%); and Group 4, keratan sulfate metabolism (31%) and inflammation (50%). Top downregulated pathways were Group 1, Inflammation (36%) and glucose/citric acid metabolism (42%); Group 2, cell signaling (38%) and glucose/citric acid metabolism (35%); Group 3, keratan sulfate metabolism (31%) and ECM/collagen processes (48%); and Group 4, glucose/citric acid metabolism (33%) and ECM/collagen processes (43%).

Conclusions:

MX-JC "collagen Type 0" upregulates pathways related to ECM/collagen formation and downregulates pathways related to inflammation suggesting that it is promising biomaterial for IL. Level of Evidence NA.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article